Clinical Trial Update: Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer [Phase 1]

View source ↗

Summary

A phase 1 trial evaluating pembrolizumab for unresectable thymoma or thymic carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8 | Phase 1 | Status: RECRUITING